hVIVO (LON:HVO) Shares Climb 8% – Here’s Why

hVIVO plc (LON:HVO) rose 8% on Wednesday. The stock traded as high as GBX 6.50 and last traded at GBX 6.48. Approximately 1,554,628 shares were traded during trading, a decline of 38% from the average session volume of 2,515,174 shares. The stock had previously closed at GBX 6.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 43.38, a current ratio of 1.21 and a quick ratio of 1.16. The business has a 50-day simple moving average of GBX 6.71 and a 200 day simple moving average of GBX 7.30. The firm has a market cap of £43.44 million, a PE ratio of -7.25 and a beta of 1.69.

hVIVO (LON:HVO) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.82) earnings per share for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. Equities research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.